Neurocrine Biosciences (NBIX) Accumulated Depreciation & Amortization (2016 - 2025)
Historic Accumulated Depreciation & Amortization for Neurocrine Biosciences (NBIX) over the last 13 years, with Q4 2025 value amounting to $118.3 million.
- Neurocrine Biosciences' Accumulated Depreciation & Amortization rose 1107.98% to $118.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $118.3 million, marking a year-over-year increase of 1107.98%. This contributed to the annual value of $118.3 million for FY2025, which is 1107.98% up from last year.
- Per Neurocrine Biosciences' latest filing, its Accumulated Depreciation & Amortization stood at $118.3 million for Q4 2025, which was up 1107.98% from $106.5 million recorded in Q4 2024.
- Neurocrine Biosciences' Accumulated Depreciation & Amortization's 5-year high stood at $118.3 million during Q4 2025, with a 5-year trough of $83.0 million in Q4 2023.
- For the 3-year period, Neurocrine Biosciences' Accumulated Depreciation & Amortization averaged around $102.6 million, with its median value being $106.5 million (2024).
- Per our database at Business Quant, Neurocrine Biosciences' Accumulated Depreciation & Amortization skyrocketed by 2831.33% in 2024 and then soared by 1107.98% in 2025.
- Neurocrine Biosciences' Accumulated Depreciation & Amortization (Quarter) stood at $83.0 million in 2023, then rose by 28.31% to $106.5 million in 2024, then increased by 11.08% to $118.3 million in 2025.
- Its last three reported values are $118.3 million in Q4 2025, $106.5 million for Q4 2024, and $83.0 million during Q4 2023.